Hollmann M, Müller-Peltzer H, Greger G, Brode E, Perucca E, Grimaldi R, Crema A
Pharmacopsychiatry. 1987 Mar;20(2):72-7. doi: 10.1055/s-2007-1017079.
The pharmacodynamic and kinetic profiles of two oral biperiden formulations (tablet with instant-release and sugar-coated tablet with slow-release) were studied in a total of 12 healthy subjects after the administration of a 4 mg dose and compared in part to placebo. Biperiden as slow-release formulation showed much slower absorption than the instant-release tablet; whereas plasma levels peaked as early as 1-2 h after administration of the tablet, with the slow-release formulation a first peak was seen approximately 4.5 h after intake in the majority of the subjects. In some subjects this was followed by a trough, in others by formation of a shoulder at around 0.5 ng/ml. In all subjects a peak of about 1.0 ng/ml was reached after 10-12 h. The instant-release tablet and the slow-release formulation showed comparable bioavailability. Plasma concentrations for the slow-release formulation at 24 h were around 0.5 ng/ml, about twice as high as those for the instant-release formulation. The ratio of peak to 24 h values showed the marked reduction which is characteristic for a slow-release formulation compared with the instant-release tablet. The subjective well-being of the volunteers was not influenced by the slow-release formulation, whereas after the instant-release tablet slight CNS effects (dizziness, drowsiness and fatigue) were reported up to 6 h after ingestion. Furthermore, objectively quantifiable pharmacodynamic ocular parameters (near-point accomodation, pupil size) and the secretion of saliva proved to be less affected by the slow-release formulation than by the instant-release tablet, or not affected at all.
在12名健康受试者中,给予4毫克剂量后,研究了两种口服比哌立登制剂(速释片剂和缓释糖衣片)的药效学和药代动力学特征,并部分与安慰剂进行了比较。作为缓释制剂的比哌立登吸收比速释片剂慢得多;速释片剂给药后1-2小时血浆水平达到峰值,而缓释制剂在大多数受试者摄入后约4.5小时出现第一个峰值。在一些受试者中随后出现谷值,在另一些受试者中在约0.5纳克/毫升处形成一个波峰。所有受试者在10-12小时后达到约1.0纳克/毫升的峰值。速释片剂和缓释制剂显示出相当的生物利用度。缓释制剂在24小时时的血浆浓度约为0.5纳克/毫升,约为速释制剂的两倍。与速释片剂相比,峰浓度与24小时浓度的比值显示出缓释制剂特有的显著降低。缓释制剂对志愿者的主观幸福感没有影响,而速释片剂摄入后长达6小时报告有轻微的中枢神经系统效应(头晕、嗜睡和疲劳)。此外,客观可量化的药效学眼部参数(近点调节、瞳孔大小)和唾液分泌受缓释制剂的影响比速释片剂小,或根本不受影响。